In 5-Year Span of FDA Accelerated Approvals in Cancer, 43% Show Confirmatory Clinical Benefit
OncLive,
Fifty-seven percent of drugs granted accelerated approval for a cancer indication showed clinical benefit in confirmatory…
El ensayo Landmark produce un nuevo estándar de primera línea para el cáncer de vejiga avanzado
Espanol.news,
MADRID – El predominio generacional de la quimioterapia en el cáncer urotelial avanzado de primera línea terminó con una…
Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer
MedPage Today,
Meeting Coverage > ESMO Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy by Charles Bankhead, Senior Editor…
S2 Episode 4: Advancing Urothelial Cancer Care: Combined Therapies
Medscape,
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple…
Jonathan Rosenberg, MD, on a Safe, Platinum-Free First-Line Combination in Advanced Bladder Cancer
MedPage Today,
This Reading Room is a collaboration between MedPage Today® and: About 50% of patients with locally advanced or metastatic…
Recap: The Expanding Treatment Paradigm for Urothelial Carcinoma
Cancer Network,
Centering discussion on clinical scenarios of urothelial carcinoma, expert oncologists review recent data and discuss how…
Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma
Cancer Cell International,
Abstract Immune checkpoint inhibitors (ICIs) have made important breakthrough in anti-tumor therapy, however, no single…
Bladder cancer: management
Pharmaceutical Journal,
After reading this article, you should be able to: Differentiate the types of bladder cancer; Understand the treatment options…
Keytruda Gets Full Approval for First-Line Advanced Urothelial Carcinoma
Cancer Therapy Advisor,
The Food and Drug Administration (FDA) has granted full approval and revised the indication for Keytruda® (pembrolizumab) for…
Keytruda Gets Full Approval for First-Line Advanced Urothelial Carcinoma
MPR,
The Food and Drug Administration (FDA) has granted full approval and revised the indication for Keytruda® (pembrolizumab) for…
FDA Converts Indication for Pembrolizumab as Frontline Therapy for Bladder Cancer to Full Approval
Cancer Network,
The FDA has granted a full approval to pembrolizumab for the treatment of cisplatin-ineligible patients with urothelial cancer…
No Survival Benefit With Pembrolizumab in Advanced Urothelial Carcinoma
Cancer Therapy Advisor,
Adding pembrolizumab to first-line chemotherapy did not significantly prolong progression-free survival (PFS) or overall…
Adding Pembrolizumab to Chemo Provides Little or No Benefit in Urothelial Cancer
Medscape,
NEW YORK (Reuters Health) - Patients with locally advanced, unresectable, or metastatic urothelial cancer may not derive extra…
First-Line Chemo Plus Immunotherapy Falls Short in Bladder Cancer
MedPage Today,
Oncology/Hematology > Other Cancers Adding pembrolizumab to cisplatin-based chemotherapy did not improve survival outcomes…